Fourth Quarter 2009 Financial Highlights
    -- Total revenues were $107.2 million, up 209% from $34.7 million in 4Q08
    -- Adjusted net income attributable to controlling interest (excluding
       non-recurring items) was $19.4 million, up 220% from $6.0 million
       in 4Q08
    -- GAAP earnings attributable to controlling interest were $0.59 per
       diluted share, compared with $0.27 in 4Q08
    -- Adjusted earnings attributable to controlling interest (excluding
       non-recurring items) were $0.62 per diluted share

    Fiscal Year 2009 Financial Highlights
    -- Total revenues were $223.2 million, up 85% from $120.8 million in 2008
    -- Adjusted net income attributable to controlling interest (excluding
       non-recurring items) was $43.8 million, up 73% from $25.4 million
       in 2008
    -- GAAP earnings attributable to controlling interest were $0.77 per
       diluted share, compared with $1.19 in 2008
    -- Adjusted earnings attributable to controlling interest (excluding
       non-recurring items) were $1.71 per diluted share

    Financial Summary for Fourth Quarter 2009 versus Fourth Quarter 2008

                                            4Q09          4Q08         YoY%
                                                                       Change

    Revenue                             $107,213,986    $34,743,375     209%

    Gross Profit                         $36,063,886    $11,489,202     214%
    Gross Profit Margin                        33.6%         33.10%      --
    Operating Income                     $25,962,245     $7,013,528     270%
    Operating Margin                           24.2%          20.2%      --
    Net Income Attributable to
     Controlling Interest                $18,319,775     $6,040,852     203%
    Adjusted Net Income Attributable to
     Controlling Interest(*)             $19,356,385     $6,040,852     220%
    Adjust Net Margin(*)                       18.1%          17.4%      --
    Diluted EPS Attributable to
    Controlling Interest                       $0.59          $0.27     119%
    Adjusted Diluted EPS Attributable to
    Controlling Interest(*)                    $0.62          $0.27     130%

    (*)See Reconciliation of non-GAAP measure to GAAP net income. Also see
       "About Non-GAAP Financial Measures" toward the end of this release

In the fourth quarter of 2009, total sales more than tripled to $107.2 million compared to $34.7 million in 4Q08, which was negatively impacted by the global financial crisis. The acquisition of Xi’an Tech Full Simo Electric Motor Co. Ltd. (”Xi’an Simo”) in October 2009 contributed approximately $44 million in the fourth quarter. Excluding this acquisition, sales in the fourth quarter increased 82% year over year. The higher sales were primarily driven by increased sales in all product lines resulting from strong economic growth in China. The linear motor propulsion systems developed by the Company for coal transportation trains contributed $7.3 million to total sales as the Company started the delivery during the quarter and 116 oil pumps were sold in 4Q09, up from 31 units in 4Q08.

Net income attributable to controlling interest in the quarter totaled $18.3 million ($0.59 per diluted share), up from $6.0 million ($0.27 per diluted share) in 4Q08. Excluding the $1.04 million non-cash charge for the change in fair value of warrants, adjusted net income for 4Q09 was $19.4 million ($0.62 per diluted share). The following table presents the reconciliation of non-GAAP measure to GAAP net income for the quarter versus 4Q08.

                                                4Q09           4Q08
    Net Income Attributable to
     Controlling Interest                   $18,319,775     $6,040,852
     Add back:
      Change in fair value of warrant        $1,036,610             $0
    Adjusted Net Income Attributable
     to Controlling Interest                $19,356,385     $6,040,852
    Diluted EPS Attributable to
     Controlling Interest                         $0.59          $0.27
     Add back:
      Change in fair value of warrant             $0.03          $0.00
    Adjusted EPS Attributable to
     Controlling Interest                         $0.62          $0.27

The table below presents the sales distribution and gross profit margin by each of our product line in 4Q09 compared to 4Q08.

                              Percent of Total
    Product Line                 Revenues             Gross Profit Margin
                              4Q09       4Q08          4Q09       4Q08
    Linear Motors and
    Related Systems           19.0%      36.9%         61.6%      52.5%
    Specialty Micro-Motors    17.2%      22.3%         37.9%      40.3%
    Rotary Motors             63.2%      36.5%         23.9%      10.5%
     Weihai                   22.1%      36.5%          9.6%      10.5%
     Xi'an                    41.1%         0%         31.6%       N/A
    Others                     0.6%       4.3%         49.3%      47.0%
    Total/Average            100.0%     100.0%         33.6%      33.1%

    Financial Summary for 2009 versus 2008

                                            2009          2008         YoY%
                                                                       Change
    Revenue                              $223,234,394  $120,820,302     85%
    Gross Profit                          $76,612,174   $47,476,781     61%
    Gross Profit Margin                          34.3%         39.3%    --
    Operating Income                      $55,847,301   $34,393,177     62%
    Operating Margin                             25.0%         28.5%    --
    Net Income Attributable to
     Controlling Interest                 $19,646,781   $25,378,699    (23)%
    Adjusted Net Income Attributable to
     Controlling Interest(*)              $43,813,233   $25,378,699     73%
    Adjusted Net Margin*                         19.6%         21.0%    --
    Diluted EPS  Attributable to
     Controlling Interest                       $0.77         $1.19    (35)%
    Adjusted Diluted EPS  Attributable
     to Controlling Interest*                   $1.71         $1.19     44%

    (*) See Reconciliation of non-GAAP measure to GAAP net income. Also see
        "About Non-GAAP Financial Measures" toward the end of this release

For the year 2009, revenues increased by 85% to $223.2 million from $120.8 million in 2008. Strong sales growth resulted from the acquisition of Xi’an Simo ($44 million) as well as higher sales across all product lines. The Company delivered 519 oil pumps compared to 214 units in 2008. Linear motor propulsion systems developed for coal transportation trains contributed $7.3 million to our sales as the Company started to deliver units during the 4th quarter.

Net income attributable to controlling interest in 2009 totaled $19.6 million ($0.77 per diluted share), which included $24.2 million charges related to non-recurring and non-cash items. Excluding these non-recurring items and non-cash charges, adjusted net income attributable to controlling interest for 2009 was $43.8 million ($1.71 per diluted share) compared to net income of $1.19 per diluted share in 2008. The following table presents the reconciliation of non-GAAP measure to GAAP net income for full-year 2009 versus 2008.

                                                         2009           2008
    Net Income Attributable to
     Controlling Interest                           $19,646,781    $25,378,699
    Deduct:
     Other Income - Government Grant                ($1,172,560)            $0
     Gain on debt repurchase                        ($4,155,000)            $0
    Add back:
     Amortization associated with debt
      repurchase                                     $7,279,487             $0
     Loss on cross currency swap
      settlement                                     $9,000,000             $0
     Change in fair value of warrant                $13,214,525             $0
    Adjusted Net Income Attributable
     to Controlling Interest                        $43,813,233    $25,378,699
    Diluted EPS                                           $0.77          $1.19
    Deduct:
     Other Income - Government Grant                    ($0.050)         $0.00
     Gain on debt repurchase                            ($0.160)         $0.00
    Add back:
     Amortization associated with debt
      repurchase                                         $0.280          $0.00
     Loss on cross currency swap
      settlement                                         $0.350          $0.00
     Change in fair value of warrant                     $0.520          $0.00
    Adjusted Diluted EPS Attributable
     to Controlling Interest                              $1.71          $1.19

The table below presents the sales distribution and gross profit margin by each of our product line in 2009 versus 2008.

                                 Percent of Total
    Product Line                    Revenues              Gross Profit Margin
                              2009             2008         2009        2008
    Linear Motors and
    Related Systems           27.2%            41.0%        59.3%       54.0%
    Specialty Micro-Motors    18.6%            28.0%        39.2%       40.0%
    Rotary Motors             52.1%            23.0%        18.9%       10.7%
     Weihai                   32.4%            23.0%        11.2%       10.7%
     Xi'an                    19.7%             0.0%        31.6%        N/A
    Others                     2.1%             8.0%        48.4%       44.7%
    Total/Average            100.0%           100.0%        34.3%       39.3%

Overall gross profit margin declined to 34.3% in 2009 from 39.3% in 2008 due to changes in the product mix as sales of lower-margin industrial rotary motors expanded, in part as a result of the acquisition of Xi’an Simo. Operating profits in 2009 were $55.8 million compared to $34.4 million in 2008.

“We are extremely pleased to have delivered the best quarter and the best year in our Company’s history despite weak economic conditions early on,” said Mr. Tianfu Yang, Chairman and Chief Executive Officer of Harbin Electric. “2009 was also a year of great strategic, operational and financial accomplishments as we further strengthened our leadership position in the electric motor industry in China. The acquisition of Xi’an Simo, one of China’s leading electric motor companies, and its successful integration allowed us to start realizing synergies and provided a solid platform for continuous growth. Faster economic growth in the second half of the year fueled by the massive government stimulus program created a positive environment for our business. On the financial front, we raised additional equity capital which allowed us to repay a significant portion of our existing indebtedness, complete the acquisition of Xi’an Simo, and maintain a strong balance sheet as we continue to implement our growth strategy. We view these record results, accomplished with the hard work and dedication of our employees, as well as the continuous support of our shareholders, as a validation of our vision, strategic focus and relentless execution.”

Looking ahead, Mr. Yang commented, “We are ready to move the Company forward to a sustained profitability in 2010 supported by a solid platform that we have built over the past years as we expect continuous growth and leverage our strong financial position and promising portfolio of products. Although the first quarter is traditionally slower with the long Chinese new-year holiday, we do not expect this seasonality to impact our business significantly compared to the fourth quarter. We also expect that the Chinese government’s commitment to sustainable economic growth and the accelerated industrialization and urbanization of China will continue to drive our business and support our long term growth objectives. We look forward to a productive 2010 as we continue to capture the synergies of the Xi’an Simo acquisition, advance R&D and strengthen growth in all core businesses. We believe that 2010 will be another strong year for Harbin Electric and we remain committed to our strategies to achieve both our near and long term goals and maximize value for our shareholders.”

Conference Call Details

The Company will host a conference call to discuss its fourth quarter and full year 2009 financial results at 8:00 a.m. ET on Wednesday, March 10, 2010. Tianfu Yang, Chairman and Chief Executive Officer, Zedong Xu, Chief Financial Officer, and Christy Shue, Executive Vice President of the Company will be on the call.

To participate in the conference call, please dial any of the following numbers:

    USA:           1-800-603-1779
    International: 1-706-643-7429
    North China:   10-800-713-0924
    South China:   10-800-130-0748

    The conference ID for the call is 55950962.

A replay of the call will be available beginning at 9:00 a.m. ET on March 10, 2010 and will remain available through midnight on March 17th, 2010.

    To access the replay, please dial any of the following numbers:

    USA:           1-800-642-1687
    International: 1-706-645-9291

    Passcode is 55950962.

This conference call will be broadcast live over the Internet. To listen to the live webcast, please go to http://www.harbinelectric.com and click on “Harbin Electric Q4 and Full Year 2009 Financial Results Conference Call.” The replay of the webcast will be available for 30 days and will be archived on the Investor Kits page of the website after 30 days.

About Non-GAAP Financial Measures

The management of Harbin Electric uses non-GAAP adjusted net earnings to measure the performance of the Company’s business internally by excluding non-recurring items as well as special non-cash charges. The Company’s management believes that these non-GAAP adjusted financial measures allow the management to focus on managing business operating performance because these measures reflect the essential operating activities of Harbin Electric and provide a consistent method of comparison to historical periods. The Company believes that providing the non-GAAP measures that management uses internally to its investors is useful to investors for a number of reasons. The non-GAAP measures provide a consistent basis for investors to understand Harbin Electric’s financial performance in comparison to historical periods without variations caused by non-recurring items and non-operating related charges. In addition, it allows investors to evaluate the Company’s performance using the same methodology and information as that used by the management. Non-GAAP measures are subject to inherent limitations because they do not include all of the expenses included under GAAP and because they involve the exercise of judgment of which charges are excluded from GAAP financial measure. However, the management of Harbin Electric compensates for these limitations by providing the relevant disclosure of the items excluded.

About Harbin Electric, Inc.:

Harbin Electric, headquartered in Harbin, China, is a leading developer and manufacturer of a wide array of electric motors with a focus on innovative, customized and value-added products. Its major product lines include industrial rotary motors, linear motors, and specialty micro-motors. The Company’s products are purchased by a broad range of domestic and international customers, including those involved in energy industry, factory automation, food processing, packaging, transportation, automobile, medical devices, machinery and tool manufacturing, chemical, petrochemical, as well as in the metallurgical and mining industries. With a recent acquisition of industrial rotary motor business, the Company operates four manufacturing facilities in China located in Xi’an, Weihai, Harbin and Shanghai.

Harbin Electric has built a strong research and development capability by recruiting talent worldwide and through collaborations with top scientific institutions. The Company owns numerous patents in China and has developed award-winning products for its customers. Relying on its own proprietary technology, the Company developed an energy efficient linear motor driving oil pump, the first of its kind in the world, for the largest oil filed in China. Its self-developed linear motor propulsion system is powering China’s first domestically made linear motor driving metro train. As China continues to grow its industrial base, Harbin Electric aspires to be a leader in the industrialization and technology transformation of the Chinese manufacturing sector. To learn more about Harbin Electric, visit http://www.harbinelectric.com .

Safe Harbor Statement

The actual results of Harbin Electric, Inc. could differ materially from those described in this press release. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in the Company’s periodic filings with the U.S. Securities and Exchange Commission, including the factors described in the section entitled “Risk Factors” in its annual report on Form 10-K for the year ended December 31, 2008. The Company does not undertake any obligation to update forward-looking statements contained in the press release. This press release contains forward-looking information about the Company that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may, “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and the Company’s future performance, operations and products.

    For investor and media inquiries, please contact:

    In China
     Harbin Electric, Inc.
     Tel:   +86-451-8611-6757
     Email: MainlandIR@Tech-full.com

    In the U.S.
     Christy Shue
     Harbin Electric, Inc.
     Executive VP, Finance & Investor Relations
     Tel:   +1-631-312-8612
     Email: cshue@HarbinElectric.com

     Kathy Li
     Christensen Investor Relations
     Tel:   +1-212-618-1987
     Email: kli@christensenir.com

                     HARBIN ELECTRIC, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                        AS OF DECEMBER 31, 2009 AND 2008
                                     ASSETS
                                              December 31,      December 31,
                                                  2009              2008

    CURRENT ASSETS:
        Cash and cash equivalents              $92,902,400       $48,412,263
        Restricted cash                          3,522,009           513,450
        Notes receivable                         1,086,929         1,451,977
        Accounts receivable, net                93,322,885        30,284,080
        Inventories                             74,913,877        21,960,084
        Other receivables & prepaid
         expenses                                5,828,453           248,552
        Advances on inventory purchases         11,718,544         3,529,607
          Total current assets                 283,295,097       106,400,013

    PLANT AND EQUIPMENT, net                   156,364,548        94,931,999

    OTHER ASSETS:
        Debt issuance costs, net                   359,255         1,672,279
        Advances on equipment purchases         10,532,902        10,416,187
        Advances on intangible assets            3,133,512         1,892,430
        Goodwill                                61,300,241        12,273,778
        Other intangible assets, net of
         accumulated amortization               14,245,984         6,430,397
        Other assets                             1,722,693           471,220
        Deposit in derivative hedge                     --         1,000,000
          Total other assets                    91,294,587        34,156,291

            Total assets                      $530,954,232      $235,488,303

                     LIABILITIES AND SHAREHOLDERS' EQUITY

    CURRENT LIABILITIES:
        Notes payable - short term              $4,533,268         1,026,900
        Accounts payable                        47,102,564         8,415,919
        Short term loan - bank                  38,291,634         4,180,950
        Short term loan - officers                 918,342                --
        Short term loan - others                 5,229,653                --
        Other payables                           8,912,586           875,395
        Accrued liabilities                      3,292,999         1,914,397
        Customer deposits                       18,455,842         1,244,622
        Taxes payable                            8,230,512         2,096,521
        Interest payable                           123,730           800,954
        Cross currency hedge payable                    --           175,986
        Current portion of notes payable,
         net                                     7,660,210         1,979,871
          Total current liabilities            142,751,340        22,711,515

    LONG TERM LIABILITIES:
        Amounts due to original
         shareholder                            28,681,976           733,500
        Long term loan - bank                    4,401,000                --
        Notes payable - long term, net                  --        31,630,995
        Fair value of derivative
         instrument                                     --         5,762,958
        Warrant liability                        4,623,558                --

            Total liabilities                  180,457,874        60,838,968

    COMMITMENTS AND CONTINGENCIES

    SHAREHOLDERS' EQUITY:
        Common Stock, $0.00001 par value,
         100,000,000 shares authorized,
         31,067,471 and 22,102,078
         shares issued and outstanding
         as of December 31, 2009 and
         2008, respectively                            310               220
        Paid-in-capital                        218,094,374        95,029,290
        Retained earnings                       69,594,113        52,100,479
        Statutory reserves                      22,869,423        14,573,994
        Accumulated other comprehensive
         income                                 18,638,297        12,945,352
          Total shareholders' equity           329,196,517       174,649,335

    NONCONTROLLING INTERESTS                    21,299,841                --

            Total liabilities and
             shareholders' equity             $530,954,232      $235,488,303

                      HARBIN ELECTRIC, INC. AND SUBSIDIARIES
         CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
               FOR THE YEARS ENDED DECEMBER 31, 2009, 2008 AND 2007

                                           For the Years ended December 31,
                                            2009         2008         2007

    REVENUES                            $223,234,394 $120,820,302 $65,402,864

    COST OF SALES                        146,622,220   73,343,521  32,967,887

    GROSS PROFIT                          76,612,174   47,476,781  32,434,977

    RESEARCH AND DEVELOPMENT EXPENSE       2,093,366    1,170,169   1,064,074

    SELLING, GENERAL AND  ADMINISTRATIVE
     EXPENSES                             18,671,507   11,913,435   7,659,611

    INCOME FROM OPERATIONS                55,847,301   34,393,177  23,711,292

    OTHER EXPENSE (INCOME), NET
        Other (income) expenses, net      (5,462,148)  (1,575,224)    188,654
        Interest expense, net             12,315,645    6,065,814   6,619,954
        Loss on cross currency hedge
         settlement                        9,000,000           --          --
        Gain on debt repurchase           (4,155,000)          --          --
        Change in fair value of warrant   13,214,525           --          --
            Total other expense, net      24,913,022    4,490,590   6,808,608

    INCOME BEFORE PROVISION FOR INCOME
     TAXES                                30,934,279   29,902,587  16,902,684

    PROVISION FOR INCOME TAXES             7,796,084    4,523,888          --

    NET INCOME BEFORE NONCONTROLLING
     INTEREST                             23,138,195   25,378,699  16,902,684

    LESS: NET INCOME ATTRIBUTABLE TO
     NONCONTROLLING INTEREST               3,491,414           --          --

    NET INCOME ATTRIBUTABLE TO
     CONTROLLING INTEREST                $19,646,781  $25,378,699 $16,902,684

    EARNINGS PER SHARE
        Basic
            Weighted average number of
             shares                       25,568,936   20,235,877  17,082,300
            Earnings per share before
             noncontrolling interest           $0.90        $1.25       $0.99
            Earnings per share
             attributable to controlling
             interest                          $0.77           --          --
            Earnings per share
             attributable to
             noncontrolling interest           $0.14           --          --

        Diluted
            Weighted average number of
             shares                       25,672,420   21,323,660  18,634,739
            Earnings per share before
             noncontrolling interest           $0.90        $1.19       $0.91
            Earnings per share
             attributable to controlling
             interest                          $0.77           --          --
            Earnings per share
             attributable to
             noncontrolling interest           $0.13           --          --

                      HARBIN ELECTRIC, INC. AND SUBSIDIARIES
         CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
              FOR THE THREE MONTHS ENDED DECEMBER 31, 2009 AND 2008

                                                    2009             2008

    REVENUES                                   $107,213,986       $34,743,375

    COST OF SALES                                71,150,100        23,254,173

    GROSS PROFIT                                 36,063,886        11,489,202

    RESEARCH AND DEVELOPMENT EXPENSE                823,255           755,438

    SELLING, GENERAL AND  ADMINISTRATIVE
     EXPENSES                                     9,278,386         3,720,236

    INCOME FROM OPERATIONS                       25,962,245         7,013,528

    OTHER EXPENSE (INCOME), NET
        Other (income) expenses, net             (1,759,234)         (620,042)
        Interest expense, net                     1,553,417           529,760
        Loss on cross currency hedge
         settlement                                      --                --
        Gain on debt repurchase                          --                --
        Change in fair value of warrant           1,036,610                --
            Total other expense (income),
             net                                    830,793           (90,282)

    INCOME BEFORE PROVISION FOR INCOME
     TAXES                                       25,131,452         7,103,810

    PROVISION FOR INCOME TAXES                    3,320,263         1,062,958

    NET INCOME BEFORE NONCONTROLLING
     INTEREST                                    21,811,189         6,040,852

    LESS: NET INCOME ATTRIBUTABLE TO
     NONCONTROLLING INTEREST                      3,491,414                --

    NET INCOME ATTRIBUTABLE TO
     CONTROLLING INTEREST                       $18,319,775        $6,040,852

    EARNINGS PER SHARE
        Basic                                         $0.59             $0.28
        Diluted                                       $0.59             $0.27

Microcyn-based products, branded as Microcyn Skin and Wound Care and Microcyn Skin & Wound HydroGel in the United States, Microdacyn60™ in Mexico, Dermacyn™ Wound Care in Europe and China and Oxum in India, have treated over two million patients worldwide without a single report of a serious adverse effect.

Noridian Administrative Services LLC, which is the pricing, data analysis and coding contractor for the Medicare program, has assigned Medicare HCPCS code #A6248 to the Microcyn HydroGel.

“We are especially excited to receive our first FDA clearance for the Microcyn HydroGel for dermatology indications including the reduction of itch and pain relief for troublesome skin afflictions,” said Hoji Alimi, founder and CEO of Oculus.

Microcyn HydroGel for dermatology indications will be commercially available in April 2010. Oculus is partnering with a series of independent sales groups in key metropolitan regions with a combined thirty-six person commissioned-based sales team experienced in dermatology, which will focus on the dermatology market including cosmetic and plastic surgeons, pediatricians, aesthetic clinics and dermatologists. For more information, pricing or pre-ordering, please telephone 1-800-931-3205.

According to a report from Business Insights, in terms of size, the United States market dominates the global dermatology market, responsible for some 41.2% of sales or $4.6 billion in 2005.

About Oculus Innovative Sciences

Oculus Innovative Sciences is a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn^® Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. The Microcyn Technology addresses the need for improved solutions in multiple markets including dermatology, oral care, cosmeceutical, wound care and others. It features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country specific regulatory clearances and approvals. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increase blood flow to the wound site, and reduce both inflammation and pain while assisting in faster wound closure. The company’s headquarters are in Petaluma, California, with operations in Latin America. More information can be found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company’s commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as “intended” and “will be,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2009. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.

Oculus Innovative Sciences, Microcyn, Dermacyn and Vetericyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

IPF is a rare and fatal lung disease that affects approximately 200,000 people in the United States and Europe. If approved by the FDA for commercialization, Esbriet would be the first medication to be made available to IPF patients in the United States.

“We are pleased with the outcome of today’s Advisory Committee meeting,” said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. “We look forward to working closely with the FDA as review of the Esbriet NDA continues.”

Though the Advisory Committee’s recommendations are not binding, they will be considered as the FDA completes its review of the New Drug Application (NDA) for Esbriet. Esbriet received Orphan Drug, Fast Track and Priority Review designations by the FDA. Priority Review designation may be granted by the FDA to an NDA for drugs that have the potential to offer major advances in treatment, or provide a treatment where no adequate therapy exists. A target date of May 4, 2010 has been set under the Prescription Drug User Fee Act (PDUFA).

Status of Esbriet (pirfenidone) in Europe

On March 2, 2010, InterMune announced that it had submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market Esbriet for the treatment of IPF patients in the European Union. Esbriet (pirfenidone) has been granted Orphan Drug status in Europe.

Conference Call and Webcast Details

InterMune will host a conference call today at 5:00 p.m. EST to discuss Esbriet. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 61659499. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company’s website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 61659499.

About Esbriet (pirfenidone)

Preclinical and in-vitro evidence has shown that Esbriet has both anti-fibrotic and anti-inflammatory effects. In February 2009, InterMune announced the results of the company’s two global Phase 3 clinical trials evaluating Esbriet for the treatment of IPF, known as the CAPACITY trials. Prior to the CAPACITY results, data had previously been presented from another Phase 3 study and three Phase 2 clinical trials in more than 400 patients which suggested that Esbriet may positively affect lung function and disease progression in patients with IPF. In those clinical studies, Esbriet was safe and generally well tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms. In October of 2008, pirfenidone was approved for use in IPF patients in Japan and is marketed as Pirespa® by Shionogi & Co. Ltd. in that country.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating and ultimately fatal disease that affects approximately 200,000 people in Europe and the United States combined, with approximately 30,000 new cases reported per year in each region.

IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough and is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20%. Patients diagnosed with IPF are usually between the ages of 40 and 70, with a median age of 63 years and the disease tends to affect slightly more men than women. There are no medicines approved in Europe and the United States for the treatment of IPF.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes Esbriet® (pirfenidone) for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY) and a New Drug Application (NDA) has been accepted for Priority Review by the FDA and a Marketing Authorization Application (MAA) has been submitted to the European Medicines Agency (EMA). The hepatology portfolio includes the HCV protease inhibitor compound RG7227 (ITMN-191) that entered Phase 2b in August 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com

.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, which reflect InterMune’s judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated regulatory timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune’s actual results could differ materially from those described in InterMune’s forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy analyses and safety results the company has submitted in support of its NDA and MAA filings. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading “Risk Factors” in InterMune’s most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the “Form 10-K”), those additional risks and uncertainties relating InterMune and its business found in the risk factors attached as Exhibit 99.3 to InterMune’s Form 8-K filed with the SEC on January 20, 2010, and in the Prospectus Supplement filed with the SEC on January 21, 2010, and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K, the Form 8-K, the Prospectus Supplement and InterMune’s other periodic reports filed with the SEC. InterMune undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in InterMune’s expectations.

- Provides Promising Biologic Intended to Treat Multiple Sclerosis and Compounds that Complement Abbott’s Existing Diverse Oncology Program

Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott’s early- and mid-stage pharmaceutical pipeline. Abbott will acquire Facet for US$27 per share in cash for a net transaction value of approximately US$450 million, which includes a purchase price of approximately US$722 million less Facet’s projected cash and marketable securities at closing of approximately US$272 million.

The acquisition brings access to biologics in two key therapeutic areas, immunology and oncology. The compounds include daclizumab – a Phase II investigational biologic intended to treat multiple sclerosis (MS) that is expected to move into Phase III development in the second quarter 2010 – and oncology compounds in early- to mid-stage development. Daclizumab is being developed in collaboration with Biogen Idec and certain oncology compounds are being developed in collaboration with other parties.

“This acquisition will further strengthen Abbott’s biologics capabilities and pharmaceutical pipeline,” said John Leonard, M.D., senior vice president, global pharmaceutical research and development, Abbott. “Daclizumab is a promising treatment for multiple sclerosis, a disease that has a significant unmet medical need, and has the potential to become an important treatment option for patients. We continue to explore multiple mechanisms to treat autoimmune diseases and cancer with both biologic and small molecule approaches.”

“We believe this transaction provides full and fair value for our stockholders and validates the potential of Facet’s clinical and technology assets, all of which has resulted from the effort and dedication of our employees,” said Faheem Hasnain, president and chief executive officer, Facet Biotech. “Abbott’s depth of expertise in immunology and oncology makes it an excellent organization to maximize the full potential of these promising clinical programs and technologies.”

Multiple sclerosis is an inflammatory disease of the central nervous system affecting more than 1 million people worldwide, and is characterized by lesions in the brain and spinal cord. Daclizumab is a humanized antibody that binds to the high affinity IL-2 receptor and selectively inhibits this receptor on activated T cells. Studies to date have shown that daclizumab may reduce the inflammatory lesions associated with MS and has the potential to offer enhanced efficacy over many existing MS therapies along with a favorable safety profile.

Facet’s oncology collaborations include early- and mid-stage compounds that are being studied to treat different types of cancer, including multiple myeloma and chronic lymphocytic leukemia.

These novel compounds in development complement Abbott’s leading-edge research in oncology, which includes three compounds in mid- to late-stage trials: ABT-263, a Bcl-2 family protein antagonist; ABT-888, a PARP inhibitor; and ABT-869, a multi-targeted kinase inhibitor.

Abbott is also advancing treatments for conditions such as Alzheimer’s disease, schizophrenia, hepatitis C and pain.

Under the terms of the agreement, Abbott will promptly commence a tender offer to purchase all outstanding shares of Facet Biotech at US$27 per share. The closing of the tender offer is conditioned on the tender of a majority of the outstanding shares of Facet’s common stock on a fully diluted basis and the satisfaction of regulatory and other customary conditions. The transaction has been approved on behalf of the boards of directors of Facet and Abbott. Approval of the transaction by Abbott’s shareholders is not required.

The transaction is expected to close in the second quarter of 2010. Abbott would expect to incur one-time specified charges following the closing of the acquisition, which will be defined at a later date. This transaction does not impact Abbott’s previously issued ongoing earnings-per-share guidance for 2010.

Centerview Partners served as financial advisor to Facet Biotech and rendered a fairness opinion to Facet Biotech’s board of directors in connection with the transaction.

About Facet Biotech

Facet Biotech is a biotechnology company dedicated to advancing its pipeline of five clinical-stage products focused in multiple sclerosis and oncology, leveraging its research and development capabilities to identify and develop new oncology drugs and applying its proprietary next-generation protein engineering technologies to potentially improve the clinical performance of protein therapeutics. Facet Biotech has development collaborations with Biogen Idec, Bristol-Myers Squibb Company and Trubion Pharmaceuticals. For additional information about the company, please visit www.facetbiotech.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott’s news releases and other information are available on the company’s Web site at www.abbott.com.

Additional Information

The tender offer for shares of Facet Biotech Corporation described in this press release has not yet commenced. This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. At the time the tender offer is commenced, Abbott will file a tender offer statement (including an offer to purchase, letter of transmittal and related tender offer documents) with the U.S. Securities and Exchange Commission (SEC) and Facet Biotech will file with the SEC a solicitation/recommendation statement with respect to the offer. Stockholders of Facet Biotech are strongly advised to read the tender offer statement and the related solicitation/recommendation statement, because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. The tender offer statement and certain other offer documents, as well as the solicitation/recommendation statement, will be made available to all stockholders of Facet Biotech at no expense to them. These documents will be available at no charge on the SEC’s web site at http://www.sec.gov.

Facet Biotech Forward Looking Statement

This press release contains forward-looking statements of Facet Biotech that are not historical facts. These forward-looking statements may be identified by words such as “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “estimate,” “target,” “project,” “could,” “should,” “may,” “will,” “would,” “continue,” “forecast,” and other similar expressions. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Various factors may cause differences between current expectations and actual results. The factors include risks and uncertainties associated with the tender offer, including uncertainties as to the timing of the tender offer and merger, uncertainties as to how many of Facet Biotech’s stockholders will tender their shares in the offer, the risk that competing offers will be made, and the possibility that various closing conditions for the transaction may not be satisfied or waived. Other factors that may cause Facet Biotech’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in Facet Biotech’s filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” sections of the Company’s periodic reports on Form 10-K and Form 10-Q filed with the SEC. Copies of Facet Biotech’s filings with the SEC may be obtained at the “Investor” section of Facet Biotech’s website at www.facetbiotech.com. Facet Biotech expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Facet Biotech’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

Abbott Forward Looking Statement

Some statements in this news release, including statements regarding the anticipated closing of the above transaction and the effect on Abbott’s financial performance, may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Among other things, these factors include the risk that the acquisition will not be completed because the tender offer did not proceed as anticipated or closing conditions to the acquisition were not satisfied. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to Abbott’s Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments. To the extent that Abbott’s statements refer to the prospects of Facet Biotech’s business, such statements are qualified by Facet Biotech’s forward looking statement language appearing above.

The non-binding provisions of the LOI contemplate a merger transaction in which Reed’s would acquire Jones Soda for a combination of cash and Reed’s common stock. The shareholders of Jones Soda would receive an aggregate of 4.5 million shares of Reed’s common stock (or approximately 0.17 of a share of Reed’s common stock per share of Jones Soda common stock based on current Jones Soda shares outstanding) and cash of $0.10 per share of Jones Soda common stock (or an aggregate of approximately $2.56 million based on current shares outstanding). There is no financing contingency as Reed’s would use its best efforts to secure the cash portion of the consideration, and if it is unable to secure all or part of this cash, any deficit would instead be paid in additional shares of Reed’s common stock, with the aggregate number of shares equal to the amount of the cash deficit divided by $1.70.

Mr. Chris Reed, Founder, Chairman and CEO of Reed’s stated, “We have watched Jones for years and have been impressed with its innovative marketing programs, strong brand recognition, and loyal customer following. I am confident that our portfolio of brands will benefit from Jones Soda’s marketing savvy as well as its organization’s deep mainstream distribution relationships. At the same time, we believe our strong infrastructure and operational capabilities will help drive important efficiencies through Jones Soda’s supply chain. With minimal customer and demographic overlap between our combined brands, we believe this transaction also provides us with compelling merchandising and growth opportunities in the years ahead.”

Jones Soda retained North Point Advisors in February 2009 to assist in evaluating the company’s strategic alternatives. Since that time, Jones has reviewed a broad range of strategic alternatives to enhance shareholder value.

Rick Eiswirth, Chairman of the Board of Jones Soda Co., stated, “Over the past year we have taken numerous steps to reduce our expenses and reinvigorate our top line in order to return to profitability. Unfortunately, the challenging economic environment combined with our current capitalization has made it extremely difficult to operate on a standalone basis. After evaluating a range of strategies aimed at improving our outlook, our Board of Directors determined that the proposed merger with Reed’s offers our shareholders the most compelling long-term benefits of the available alternatives. We believe the combination of Jones and Reed’s will create a substantially larger beverage business with a more powerful operating platform and a brighter future. We are especially pleased that the Jones shareholders will be able to participate in the potential upside of the combined business, as a meaningful portion of the consideration is in the form of Reed’s stock.”

Jones Soda also announced that Joth Ricci will be stepping down as Chief Executive Officer effective April 2, 2010 in order to pursue other business opportunities. Joth Ricci commented, “I have truly enjoyed my time at Jones Soda and I’m pleased with the work our team has done to improve many aspects of our business. Unfortunately, due to the current market conditions, it has taken longer than anticipated to produce the necessary top line results to effectively return to profitability and stem our cash burn. However, I remain confident in the strength of the Jones Soda brand and believe the proposed merger with Reed’s provides Jones Soda an improved platform from which to capitalize on its future prospects and is in the best interests of its shareholders.”

Under the binding provisions of the LOI, Reed’s and Jones Soda have until April 5, 2010 to negotiate a definitive agreement on an exclusive basis. If Jones Soda receives an unsolicited acquisition, financing or other strategic transaction proposal that the Board of Directors of Jones Soda determines is superior to the proposed merger transaction with Reed’s, then Jones Soda may terminate the LOI and reimburse Reed’s for its third party out-of-pocket expenses (not to exceed $75,000).

Since the transaction terms of the LOI are non-binding, they are subject to the negotiation, execution and delivery of a definitive agreement approved by the respective Boards of Directors of each company. Accordingly, the proposed terms of the transaction are subject to change, and there can be no assurance that Reed’s and Jones Soda will enter into a definitive agreement on the terms outlined above, if at all, or that any transaction between the parties will ultimately be consummated. The companies do not intend to disclose developments with respect to negotiation of the definitive agreement until their respective Boards of Directors deem it appropriate.

The transaction would also be subject to approval of the shareholders of both Jones Soda and Reed’s.

About Reed’s, Inc.

Reed’s, Inc. makes top selling sodas in natural food markets nationwide and is currently selling in 10,500 supermarkets in natural foods and mainstream. Its six award-winning non-alcoholic Ginger Brews are unique in the beverage industry, being brewed, not manufactured and using fresh ginger, spices and fruits in a brewing process that predates commercial soft drinks.

In addition, the Company owns a top selling root beer line in natural foods, the Virgil’s Root Beer product line, and a top selling cola line in natural foods, the China Cola product line. Recently, Reed’s added the Sonoma Sparkler brands to its line, a celebration drink with an established customer base. Other product lines include: Reed’s Ginger Candies and Reed’s Ginger Ice Creams.

Reed’s products are sold through specialty gourmet and natural food stores, mainstream supermarket chains, retail stores and restaurants nationwide, and in Canada. For more information about Reed’s, please visit the company’s website at: http://www.reedsgingerbrew.com or call 800-99-REEDS.

Follow Reed’s on Twitter at: http://www.twitter.com/reedsgingerbrew

Reed’s Facebook Fan Page at: http://www.facebook.com/pages/Reeds-Ginger-Brew-and-Virgils-Natural-Sodas/57143529039?ref=nf

Subscribe to Reed’s RSS feed at: http://www.irthcommunications.com/REED_rss.xml

More information can be found at: http://www.irthcommunications.com/clients_REED.php

About Jones Soda Co.

Headquartered in Seattle, Washington, Jones Soda Co. ^® markets and distributes premium beverages under the Jones Soda, Jones Pure Cane Soda™, Jones 24C™, Jones GABA^®, Jones Organics™, Jones Naturals^® and Whoopass Energy Drink^® brands and sells through its distribution network in markets primarily across North America. A leader in the premium soda category, Jones is known for its variety of flavors and innovative labeling technique that incorporates always-changing photos sent in from its consumers. Jones Soda is sold through traditional beverage retailers. For more information visit www.jonessoda.com, www.myjones.com, and www.jonesGABA.com.

Additional Information and Where to Find It

If Reed’s and Jones enter into a definitive agreement relating to the proposed merger, Reed’s plans to file with the SEC a Registration Statement on Form S 4 in connection with the transaction, and Jones Soda plans to file with the SEC and mail to its shareholders a Proxy Statement/Prospectus in connection with the transaction. The Registration Statement and the Proxy Statement/Prospectus will contain important information about Reed’s, Jones Soda, the transaction and related matters. Investors and shareholders are urged to read the Registration Statement and the Proxy Statement/Prospectus carefully when they are available. Investors and shareholders will be able to obtain free copies of the Registration Statement and the Proxy Statement/Prospectus and other documents filed with the SEC by Reed’s and Jones Soda through the web site maintained by the SEC at www.sec.gov. In addition, investors and shareholders will be able to obtain free copies of the Registration Statement and the Proxy Statement/Prospectus from Reed’s by contacting Andrew W. Haag at IRTH Communications at (866) 976-4784, or from Jones Soda by contacting Michael O’Brien at (206)-624-3357.

Reed’s and its directors and executive officers, and Jones Soda and its directors and officers, may be deemed to be participants in the solicitation of proxies from the shareholders of Jones Soda in connection with the transaction described herein. Information regarding the special interests of these directors and executive officers in the transaction described herein will be included in the Proxy Statement/Prospectus described above. Additional information regarding the directors and executive officers of Jones Soda is also included in Jones Soda’s annual report on Form 10-K filed with the SEC on March 16, 2009. Additional information regarding the directors and executive officers of Reed’s is also included in Reed’s annual report on Form 10-K filed with the SEC on March 27, 2009, as amended.

Forward-Looking Statements Disclosure

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the potential future benefits of the proposed merger, including growth opportunities for each company’s brands, the combined company’s ability to realize cost efficiencies, and the ability of Reed’s infrastructure and operational capabilities to drive efficiencies through Jones Soda’s supply chain. Forward-looking statements include all passages containing words such as “aims,” “anticipates,” “becoming,” “believes,” “continue,” “estimates,” “expects,” “future,” “intends,” “plans,” “predicts,” “projects,” “targets,” or “upcoming,” variations of such words, and similar expressions. Forward-looking statements also include any other passages that are primarily relevant to expected future events or that can only be evaluated by events that will occur in the future. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The risks and uncertainties that may affect forward-looking statements include, among others, the inability of the parties to reach a definitive agreement on the terms outlined in this press release, if all, or to consummate the transaction for any reason, including as a result of the failure to satisfy any condition to closing set forth in the definitive agreement; the inability of the combined business to achieve levels of revenue and cost reductions that are adequate to support its capital and operating requirements, or to generate sufficient cash flow from operations, or to obtain funds through additional financing, to support its business plan; the impact of current and any future adverse economic conditions; the inability of the combined business to establish distribution arrangements with distributors, retailers or national retail accounts, or to maintain relationships with its co-packers or third party brewers, or to maintain a consistent and cost-effective supply of raw materials, or to maintain brand image and product quality, or to protect its intellectual property; the impact of increasing costs of fuel and freight; the impact of competition; and other factors detailed from time to time in Jones Soda’s and Reed’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. You should not place undue reliance upon any such forward-looking statements, which are based on management’s beliefs and opinions at the time the statements are made, and neither Jones Soda nor Reed’s undertakes any obligations to update forward-looking statements should circumstances or management’s beliefs or opinions change.

“RFM’s ultra-low power short-range radio, Virtual Wire™, has been designed into various medical devices in recent years. This business, along with our custom modules, specific to medical applications, has driven this market segment to as much as 24% of our total business in recent quarters. There are multiple applications for RFM’s enabling products ranging from diagnostic communication devices to patient monitoring equipment. These applications give us a solid footprint into a rapidly growing wireless market for years to come. We continue to seek additional innovative opportunities as M2M standards emerge in the medical market,” said David M. Kirk, President and CEO of RFM.

These wireless systems, meet Federal Communications Commission (FCC) and Medical Implant Communications Services (MICS) guidelines. The ultra-low power Virtual Wire™ transceiver is an enabling technology. Other medical industry standards, such as the Continua Health Alliance standards and the Wireless Medical Telemetry Standard (WMTS), are also opportunities for RFM’s broad product portfolio.

About RFM

RF Monolithics, Inc., headquartered in Dallas, Texas, is a provider of solutions-driven, technology-enabled wireless connectivity for a broad range of wireless applications—from individual standardized and custom components to modules for comprehensive industrial wireless sensor networks and machine-to-machine (M2M) technology. For more information on RF Monolithics, Inc., please visit the Company’s website at http://www.RFM.com.

About MICS

Medical Implant Communications Service (MICS) is an ultra-low power, unlicensed, mobile radio service for transmitting data in support of diagnostic or therapeutic functions associated with implanted medical devices. The MICS permits individuals and medical practitioners to utilize ultra-low power medical implant devices, such as cardiac pacemakers and defibrillators, without causing interference to other users of the electromagnetic radio spectrum. MICS transmitters may not operate with an effective isotropic radiated power (EIRP) greater than 25 microwatts. MICS transmitter emissions are limited to an authorized bandwidth of 300 kHz and must maintain a frequency stability of +/-100 ppm of the operating frequency. Operations rules and technical regulations applicable to MICS transmitters are found within 47 CFR 95.601-95.673 Subpart E.

About WMTS

The wireless medical telemetry standard (WMTS) was officially adopted by the Federal Communications Commission (FCC) on June 8, 2000. The service rules for the equipment and use of the WMTS include limitations on transmitter output power, out of band emissions, and protection of other services. WMTS designated frequency ranges are 608 to 614 MHz; 1395 to 1400 MHz; and 1429 to 1432 MHz. WMTS generally is the remote monitoring of a patient’s health through radio technology. The use of wireless medical telemetry gives patients greater mobility and increased comfort by freeing them from the need to be connected to hospital equipment that would otherwise be required to monitor their condition. Wireless medical telemetry also serves the goal of reducing health care costs because it permits the remote monitoring of several patients simultaneously. All types of communications except voice and video are permitted on both a bi-directional and unidirectional basis, provided that all communications are related to the provision of medical care.

About Continua

Continua Health Alliance is a non-profit, open industry coalition of health care and technology companies joining together in collaboration to improve the quality of personal health care. With more than 220 member companies around the world, Continua is dedicated to establishing a system of interoperable personal health solutions with the knowledge that extending those solutions into the home fosters independence, empowers individuals and provides the opportunity for personalized health and wellness management.

Forward-Looking Statements

This news release contains forward-looking statements, made pursuant to the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Statements of the plans, objectives, expectations and intentions of RFM and/or its wholly-owned subsidiaries (collectively, the “Company” or “we”) involve risks and uncertainties. Statements containing terms such as “believe,” “expect,” “plan,” “anticipate,” “may” or similar terms are considered to contain uncertainty and are forward-looking statements. Such statements are based on information available to management as of the time of such statements and relate to, among other things, expectations of the business environment in which we operate, projections of future performance, perceived opportunities in the market and statements regarding our mission and vision, future financial and operating results. Such statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions, including risks related to economic conditions as related to our customer base, collection of receivables from customers who may be affected by economic conditions, maintaining favorable terms of sales with customers and suppliers, the highly competitive market in which we operate, rapid changes in technologies that may displace products sold by us, declining prices of products, our reliance on distributors, delays in product development efforts, uncertainty in customer acceptance of our products, changes in our level of sales or profitability, manufacturing and sourcing risks, availability of materials, cost of components for our products, product defects and returns, as well as the other risks detailed from time to time in our SEC reports, including the report on Form 10-K for the year ended August 31, 2009. We do not assume any obligation to update any information contained in this release.

The new facilities are located in Special Economic Zones (SEZ).  The cost and tax structures of SEZ facilities would help sustain EXL’s competitiveness in the global market.  With the addition of these two facilities, EXL will have 16 delivery centers and offices spread across ten locations in six countries.

“It is essential for EXL to provide our clients with a world-class infrastructure that meets their multi-shore global delivery requirements.  The expanded service delivery will effectively sustain our leadership position while creating new value propositions for our clients,” said Rohit Kapoor, President and Chief Executive Officer of EXL.  ”Noida and Jaipur are strategic locations because both these regions offer rich talent pools, robust support infrastructure and are in close proximity to several other EXL delivery centers.”

The new Noida facility will have a capacity of over 800 seats spread over 100,000 square feet in the first phase and another 1400 spread over 120,000 square feet in the second phase. The first phase is expected to be operational in the third quarter of 2010. Noida is currently home to six delivery centers of EXL.

The Jaipur facility will be EXL’s first center in a tier two Indian location. Jaipur is located approximately 250 kilometers from New Delhi.  It is an attractive location due to lower operating costs and ease of access to a qualified talent pool. This facility will have a capacity of approximately 500 seats spread over 38,000 square feet and is expected to be operational in the second quarter of 2010. EXL will focus on providing finance and accounting and transaction processing services from this facility.

About ExlService Holdings, Inc.

ExlService Holdings, Inc. (Nasdaq: EXLS) is a leading provider of outsourcing and transformation services. EXL’s outsourcing services include a full spectrum of business process outsourcing services from offshore delivery centers requiring ongoing process management skills. Transformation services enable continuous improvement of client processes by bringing together EXL’s capabilities in decision analytics, risk and financial management and operations and process excellence services. Headquartered in New York, EXL primarily serves the needs of Global 1000 companies in the insurance, utilities, financial services, transportation and travel sectors. Find additional information about EXL at www.exlservice.com.

This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to the Company’s operations and business environment, all of which are difficult to predict and many of which are beyond the Company’s control. Forward-looking statements include information concerning the Company’s possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based on assumptions that we have made in light of management’s experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although the Company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect the Company’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors are discussed in more details in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2008. These risks could cause actual results to differ materially from those implied by forward-looking statements in this release.

You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect the Company. The Company has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

“We’re excited that XIAFLEX is now available to Dupuytren’s contracture patients after many years of hard work,” said Thomas Wegman, President of BioSpecifics. “In addition our shareholders will benefit as we begin to receive royalties, as well as a markup on cost of goods sold and other payments. We look forward to XIAFLEX’s future success.”

The Company’s partner, Auxilium Pharmaceuticals Inc., announced earlier today that the Company has established a distribution system that will allow health care providers to access XIAFLEX in an office setting through specialty distributors and specialty pharmacies or, in the institutional setting, through selected wholesalers. Physicians can receive XIAFLEX after they have undergone training on XIAFLEX, and enrolled themselves and their site of care in the distribution network.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for eleven clinical indications, three of which include: Dupuytren’s contracture, Peyronie’s disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium has announced the approval of XIAFLEX by the FDA in the U.S. for the treatment of Dupuytren’s contracture. Pfizer, Inc. is responsible for marketing XIAFLEX in Europe. More information about the company may be found on its website at www.biospecifics.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the company’s strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, its expected revenue growth, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the ability of its partner Auxilium to achieve a successful launch of XIAFLEX for Dupuytren’s in the United States, obtain regulatory approval of XIAFLEX™ in the United States for Peyronie’s disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX™ in its territory for Dupuytren’s contracture and Peyronie’s disease, which will determine the amount of milestone, royalty and sublicense income payments it may receive; the amount of earn out payments it may receive from DFB Biotech Inc. and its affiliates; whether Auxilium exercises its option under the Company’s license and development agreement for additional indications; the potential benefits of its existing license and development agreements; its estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company’s Form 10-K for the year ended December 31, 2008 and the Form 10-Q for the quarter ended September 30, 2009 and any subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    -  $6.2 million in funding to Ballard for fuel cell research and
       development projects
    -  Ballard will collaborate with leading U.S. technology partners
    -  Projects will focus on fuel cell durability and cost to enable
       widespread commercialization of fuel cells for diverse applications

VANCOUVER, March 8 /PRNewswire-FirstCall/ – Ballard Power Systems (TSX: BLD; NASDAQ: BLDP) announced today that it has $6.2 million in project funding from the U.S. Department of Energy (DOE) under contract over a four year period. Ballard Material Products, a U.S. subsidiary of Ballard Power Systems, was awarded $4.1 million as prime for a contract that will focus on improvements in fuel cell durability and cost. Additionally, Ballard will be sub-contractor to leading U.S. technology organizations for several other fuel cell research and development projects funded by the DOE.

“We are excited to be working with a technology leader such as Ballard Power Systems,” said Dr. Rod Borup, Fuel Cell Program Manager, Institute for Hydrogen and Fuel Cell Research at Los Alamos National Laboratory, one of Ballard’s project partners. “This is important work in support of the DOE goal to move fuel cell technology closer to large scale commercialization. Our collaborations with Ballard are in the areas of understanding and improving fuel cell durability and reducing technology cost, which are the primary enablers to rapid market adoption of fuel cell systems.”

Over eighty percent of the announced DOE funding has been allocated to projects aimed at increased durability and cost reduction, with the remaining funds focused on water management modeling. The project for which Ballard Material Products will be prime is meant to improve the understanding of fuel cell materials and components degradation, leading to recommended mitigation strategies to facilitate further commercialization. Resulting advancements will facilitate commercialization of fuel cells for a range of applications, including stationary power generation.

In addition to Los Alamos National Laboratory, Ballard will be partnering with other leading U.S. technology organizations, including Lawrence Berkeley National Laboratory, Sandia National Laboratory, Georgia Institute of Technology, Michigan Technical University, University of Hawaii at Manoa and University of New Mexico.

“The receipt of significant funding from the DOE clearly demonstrates the Department of Energy’s interest in fuel cell market adoption,” said Dr. Christopher Guzy, Chief Technology Officer at Ballard Power Systems. “This funding is completely aligned with Ballard’s plans to continue investing in strategic enhancements of non-automotive fuel cell products.”

About Ballard Power Systems

Ballard Power Systems (TSX: BLD; NASDAQ: BLDP) provides clean energy fuel cell products enabling optimized power systems for a range of applications. To learn more about Ballard, please visit www.ballard.com.

CONTACT: Investor Relations: Lori Rozali, (604) 412-3195, investors@ballard.com; Public Relations: Guy McAree, (604) 412-7919, media@ballard.com